vorinostat(redirected from Suberoylanilide hydroxamic acid)
Also found in: Acronyms.
vorinostat(vor-in-o-stat ) ,
Pregnancy Category: D
Pharmacologic: enzyme inhibitors
Pharmacologic: enzyme inhibitors
Treatment of skin manifestations cutaneous T-cell lymphoma (CTCL) that has not responded to two systemic therapies.
Acts as a histone deacetylase inhibitor which decreases gene transcription resulting in cell cycle arrest.
Decreased progression of CTCL.
Absorption: Well absorbed following oral administration.
Distribution: Crosses the placenta.
Metabolism and Excretion: Mostly metabolized, <1% excreted unchanged in urine.
Half-life: 2 hr.
Time/action profile (blood levels)
|PO||unknown||4 hr||24 hr|
Contraindicated in: Severe hepatic impairment; Obstetric / Lactation: Pregnancy or lactation.
Use Cautiously in: Renal impairment; Mild or moderate hepatic impairment; Geriatric: May be more sensitive to drug effects; Pre-existing nausea, vomiting, diarrhea (treat symptomatically before initiating therapy); Pediatric: Safety not established.
Adverse Reactions/Side Effects
Central nervous system
- pulmonary embolism (life-threatening)
- deep vein thrombosis
- QTc interval prolongation
- anorexia (most frequent)
- constipation (most frequent)
- diarrhea (most frequent)
- dry mouth (most frequent)
- dysgeusia (most frequent)
- nausea (most frequent)
- vomiting (most frequent)
- hyperglycemia (most frequent)
- anemia (most frequent)
- thrombocytopenia (most frequent)
- weight loss (most frequent)
- muscle spasms
- chills (most frequent)
- fever (most frequent)
Drug-Drug interaction↑ risk of thrombocytopenia and GI bleeding with valproic acid.May ↑ risk of bleeding with warfarin.
Oral (Adults) 400 mg daily; if intolerance occurs dose may be ↓ to 300 mg daily or 300 mg daily for 5 consecutive days/wk.
Capsules: 100 mg
- Monitor ECG prior to and periodically during therapy.
- Assess for nausea, vomiting, and diarrhea during therapy. Administer anti-emetic and antidiarrheal medications as needed. Maintain fluid and electrolyte balances to prevent adverse effects.
- Lab Test Considerations: Monitor CBC and blood chemistry tests, including electrolytes (potassium, magnesium, calcium), glucose, and serum creatinine, every 2 wks during first 2 mo of therapy and monthly thereafter. Correct hypokalemia and hypomagnesemia before initiating therapy.
- May cause thrombocytopenia and anemia requiring dose reduction or discontinuation.
- May cause hyperglycemia requiring diet or insulin modification.
- May cause proteinuria.
Potential Nursing DiagnosesRisk for injury (Adverse Reactions)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)
- Oral: Administer once daily with food. Capsules should be swallowed whole; do not open, crush, or chew.
- Instruct patient to take vorinostat as directed. Take missed doses as soon as remembered. If almost time for next dose, skip dose and take next dose at regular time; do not double doses.
- Advise patient to drink at least 2 L of fluid/day to prevent dehydration and to report vomiting or diarrhea to health care professional promptly.
- Instruct patient to notify health care professional immediately if signs of deep vein thrombosis (sudden swelling in leg, pain or tenderness in leg (may only be felt when standing or walking), increased warmth in the area of swelling, skin redness or change in skin color) or pulmonary embolus (sudden sharp chest pain, shortness or breath, cough with bloody secretions, sweating, rapid pulse, fainting, feeling anxious) occur. Also notify health care professional if unusual bleeding or bruising, or unusual tiredness occur.
- Advise diabetic patients to monitor blood glucose frequently as directed and notify health care professional if blood sugar is higher than normal.
- May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
- May have teratogenic effects. Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
- Improvement in or decreased progression of CTCL.
Drug Guide, © 2015 Farlex and Partners